The current therapeutic scenario for relapsed mantle cell lymphoma
暂无分享,去创建一个
[1] M. Stauch,et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.
[2] N. Schmitz,et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] P. Hari,et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] J. Friedberg,et al. The Bruton tyrosine kinase (BTK) inhibitor PCI‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib , 2013, British journal of haematology.
[5] G. Pizzolo,et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Advani,et al. Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma , 2012 .
[7] A. Rosenwald,et al. Cell Proliferation (Ki-67) As Prognostic Marker in Mantle Cell Lymphoma. , 2012 .
[8] J. Vose,et al. A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) , 2012 .
[9] A. Roberts,et al. The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study , 2012 .
[10] J. Armitage,et al. Phase I/II Trial of Ofatumumab/Lenalidamide for Patients with Relasped/Refractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma , 2012 .
[11] E. Macintyre,et al. Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study , 2012 .
[12] Michael L. Wang,et al. Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up , 2012 .
[13] L. Kanz,et al. Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma , 2012, Bone Marrow Transplantation.
[14] A. Look,et al. The requirement for cyclin D function in tumor maintenance. , 2012, Cancer cell.
[15] N. Kröger,et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. Radford,et al. Single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences , 2012, British journal of haematology.
[17] R. Advani,et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] W. Klapper,et al. Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.
[19] P. Mclaughlin,et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. , 2012, The Lancet. Oncology.
[20] R. Houot,et al. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] L. Staudt,et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. , 2012, Blood.
[22] A. D. Van den Abbeele,et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. , 2012, Blood.
[23] M. Coleman,et al. Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen , 2012, Hematology.
[24] S. Pileri,et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers , 2012, Haematologica.
[25] F. Angrilli,et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi , 2012, British journal of haematology.
[26] A. Ivanova,et al. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma , 2012, Leukemia & lymphoma.
[27] C. Carlo-Stella,et al. Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study , 2011 .
[28] M. Dreyling,et al. Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial , 2011 .
[29] A. Chott,et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma , 2011, Haematologica.
[30] J. Vose,et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] Jeffrey S. Johnston,et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma , 2011, Cancer.
[32] A. Feldman,et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. , 2011, The Lancet. Oncology.
[33] John D. Roberts,et al. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms , 2011, Clinical Cancer Research.
[34] Derick R. Peterson,et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. , 2011, Blood.
[35] A. Zelenetz,et al. Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma , 2011, Clinical Cancer Research.
[36] Peter Martin,et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Gascoyne,et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172) , 2011, Leukemia & lymphoma.
[38] A. Wiestner,et al. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. , 2011, Blood.
[39] C. Haioun,et al. Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program. , 2010 .
[40] G. Salles,et al. Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL , 2010 .
[41] H. Einsele,et al. Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m2/d Is Tolerable and Highly Effective , 2010 .
[42] Michael L. Wang,et al. Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma , 2010, British journal of haematology.
[43] J. Leonard,et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma , 2010, Cancer.
[44] Thomas S. Lin,et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Michael L. Wang,et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] B. Coiffier,et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] L. Medeiros,et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. , 2009, Blood.
[48] E. Hoster,et al. Improvement of overall survival in advanced stage mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] W. Hiddemann,et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study , 2009, Leukemia & lymphoma.
[50] I. Lossos,et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] E. Kimby,et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.
[52] H. Einsele,et al. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.
[53] D. Moore,et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group , 2008, Leukemia & lymphoma.
[54] S. Fernández de Mattos,et al. Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma , 2007, Leukemia & lymphoma.
[55] J. Leonard,et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] M. Hansmann,et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] Michael L. Wang,et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] A. Zelenetz,et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] A. Bankier,et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. , 2004, Blood.
[60] Ryan D. Morin,et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. , 2012, Blood.
[61] J. Leonard,et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.